- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | XOMA Royalty schließt Übernahme von LAVA Therapeutics ab | 2 | Investing.com Deutsch | ||
| XOMA CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| Fr | XOMA Royalty completes acquisition of LAVA Therapeutics | 1 | Investing.com | ||
| Fr | XOMA Royalty Corporation: XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. | 179 | GlobeNewswire (Europe) | EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of... ► Artikel lesen | |
| Fr | Spotlight Stock Market: Market Notice 209/25 - Information regarding the rights issue from Xoma AB | 1 | Cision News | ||
| Fr | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | XOMA Royalty secures 87% of LAVA Therapeutics shares in tender offer | 4 | Investing.com | ||
| 13.11. | Leerink Partners raises XOMA stock price target to $58 on royalty outlook | 1 | Investing.com | ||
| 13.11. | XOMA: Leerink Partners hebt Kursziel wegen positiver Lizenzaussichten auf 58 $ | 2 | Investing.com Deutsch | ||
| 12.11. | XOMA GAAP EPS of $0.70 beats by $0.74, revenue of $9.35M misses by $2.12M | 2 | Seeking Alpha | ||
| 12.11. | XOMA Royalty Corporation: XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements | 717 | GlobeNewswire (Europe) | Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed... ► Artikel lesen | |
| 12.11. | XOMA Royalty Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.11. | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings | ||
| 10.11. | LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline | 131 | GlobeNewswire (Europe) | UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ("LAVA") (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed... ► Artikel lesen | |
| 24.10. | Mural Oncology: Aktionäre geben grünes Licht für Übernahme durch XOMA-Tochter | 10 | Investing.com Deutsch | ||
| 24.10. | Mural Oncology plc: Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty | 185 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION... ► Artikel lesen | |
| 17.10. | Xoma and Lava buyout cools with lower cash offer and closing conditions | 1 | FierceBiotech | ||
| 17.10. | XOMA Royalty and LAVA Therapeutics amend acquisition agreement terms | 3 | Investing.com | ||
| 17.10. | XOMA Royalty und LAVA Therapeutics passen Bedingungen der Übernahmevereinbarung an | 3 | Investing.com Deutsch | ||
| 17.10. | XOMA Royalty Corporation; LAVA Therapeutics N.V.: XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement | 382 | GlobeNewswire (Europe) | - Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands... ► Artikel lesen | |
| 03.10. | XOMA Royalty Corp - 8-K, Current Report | 13 | SEC Filings |
1 2 3 4 5 Weiter >>
84 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 73,06 | -2,53 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| QIAGEN | 41,790 | +1,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,53 | +0,50 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| JANUX THERAPEUTICS | 34,670 | +10,01 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 183,84 | -3,93 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| ADMA BIOLOGICS | 19,180 | +4,69 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 26,050 | +3,97 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,695 | +4,46 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,365 | +0,46 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| DYNE THERAPEUTICS | 20,820 | -3,92 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| NUVALENT | 109,68 | +0,28 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,700 | +3,01 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| ARS PHARMACEUTICALS | 9,300 | +15,67 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) | $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,110 | -1,10 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,80 | +4,41 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen |
Das Unternehmen XOMA CORPORATION PREF kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 22,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA CORPORATION PREF finden Sie auf Wallstreet Online.